JUUL: A Case Study in Controversy

2026-Oct-24 10:56AM EDT (Sat)

JUUL Labs became the dominant e-cigarette brand in the United States, capturing approximately 75% of the market by 2019. However, its rise was accompanied by significant controversy and legal scrutiny.

Product Details

Device: Sleek, rectangular vaping device with magnetic pod attachment
Pods (JUULpods): Pre-filled, closed-system nicotine cartridges
Nicotine concentration: 5% (59 mg/ml)—significantly higher than the EU/UK cap of 20 mg/ml
Nicotine formula: Nicotine salts (chemical formulation that reduces harshness, enabling higher concentrations)
Nicotine content: One JUUL pod contains approximately the same nicotine as 20 cigarettes

[1][2][3]

Company Status

Headquarters

Current HQ: Washington, D.C. (1000 F St NW, 8th Floor)
Former HQ: San Francisco, California (123 Mission Street)
The company purchased the 29-story, 360,000 square foot building in 2019 for $397 million
Abandoned the office less than a year later, listed it for sale expecting $450 million
No successful purchase offers materialized
In March 2026, investors (Madison Capital and PGIM) bought the debt for $90-100 million (less than 25% of pre-pandemic value)
The company relocated to Washington, D.C., likely for lobbying purposes given regulatory scrutiny [45][46][47]

Company Overview

Metric	Value
Status	Active, privately held
Employees	~720-1,200
Annual Revenue	~$1.5 billion
Total Funding	$16 billion+
Countries Operating	24
CEO	K.C. Crosthwaite

[44][45][48]

Current Business Status

Yes, JUUL is still in business in the USA.

In July 2025, the FDA granted JUUL marketing authorization for their products:

FDA Decision: July 17, 2025 - Marketing Granted Orders (MGOs) for the JUUL System [49][50]
Products Authorized: JUUL device + Virginia Tobacco and Menthol flavored JUULpods (3% and 5% nicotine) [49]
Data: JUUL submitted 110+ scientific studies, including a 2-year longitudinal cohort study showing 38-52% of adult smokers switched completely to JUUL [49][50]
Note: FDA originally ordered a ban in 2022 but reversed course days later. The authorization is not "FDA approval" - it means the products meet the "appropriate for protection of public health" standard [49][50][51]

Congressional Hearings

The House Committee on Oversight and Reform's Subcommittee on Economic and Consumer Policy held two days of hearings:

Date	Hearing	Serial No.
July 24, 2019	Examining JUUL's Role in the Youth Nicotine Epidemic: Part I	116-51
July 25, 2019	Examining JUUL's Role in the Youth Nicotine Epidemic: Part II	116-54

Chairman: Rep. Raja Krishnamoorthi

Key witnesses: James Monsees (Co-Founder/CPO), Ashley Gould (CAO), public health experts, parents, teenagers

Documents: ~55,000 non-public documents produced to the Subcommittee. [4][5]

FDA Warning Letter (September 9, 2019)

The FDA issued a warning letter citing violations of Section 911 of the Federal Food, Drug, and Cosmetic (FD&C) Act:

Violations

Marketing unauthorized modified risk tobacco products
Claiming products were "99% safer than cigarettes"
Claiming products were "much safer than cigarettes"
Describing products as "totally safe"
Marketing as "a safer alternative than smoking cigarettes"

[6][7]

FDA Questions

Why use nicotine salts? (reduces harshness, enables ~3x higher concentration)
Why 5% nicotine concentration?
School presentations telling students JUUL was "totally safe"

[1][6]

Federal Litigation (MDL)

Case: In Re: Juul Labs, Inc., Marketing, Sales Practices, and Products Liability Litigation

Court: U.S. District Court, Northern District of California

Case No.: 3:19-md-02913-WHO

Judge: William H. Orrick

MDL Order: October 2019 [8]

Settlements

Date	Settlement	Amount
December 2022	Class Action (Economic Loss)	$255 million
May 2023	Altria Group	$235 million
September 2023	Final Approval	$255 million

The MDL consolidated ~5,000 cases with ~10,000 plaintiffs (personal injury, consumer class, government entities, tribes). [8][9]

State Attorney General Settlements

Date	States/Jurisdictions	Amount
December 2022	33-34 states	$438.5 million
April 2023	CA, CO, DC, IL, MA, NM, NY	$462 million

The April 2023 $462 million settlement was the largest multistate settlement with JUUL. State allocations: California $175.8M, New York $112.7M, Illinois $67.6M, Massachusetts $41M. [10][11][12]

"Nicotine is a Drug" Argument

Public health organizations argued JUUL should be regulated as a drug/device:

Marketing implied the product helped smokers "switch" or quit—therapeutic claims requiring FDA drug approval
Under the FDA's "Tobacco Intended Use Rule," products marketed for smoking cessation require approval as drugs/devices
Selling without requisite drug approval = illegal marketing under the FD&C Act [13][14]